Research Article

The Association of the Metabolic Syndrome with PAI-1 and t-PA Levels

Christopher S. Coffey,1 Folkert W. Asselbergs,2 Patricia R. Hebert,3 Hans L. Hillege,4 Qing Li,5 Jason H. Moore,6 and Wiek H. van Gilst7

1 Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA 52242, USA
2 Division of Heart and Lungs, Department of Cardiology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
3 Charles E. Schmidt College of Biomedical Science, Florida Atlantic University, Boca Raton, FL 33431, USA
4 Department of Cardiology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands
5 Clinical Affairs and Medical Communications, ConvaTec, Inc., Skillman, NJ 08558, USA
6 Departments of Genetics and Community and Family Medicine, Dartmouth Medical School, Lebanon, NH 03756, USA
7 Department of Experimental Cardiology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands

Correspondence should be addressed to Christopher S. Coffey, christopher-coffey@uiowa.edu

Received 16 September 2010; Revised 12 January 2011; Accepted 9 February 2011

Academic Editor: Ken Ichi Aihara

Copyright © 2011 Christopher S. Coffey et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. We used a random sample (n = 2,495) from the population-based Prevention of Renal and Vascular End-stage Disease (PREVEND) study population to examine the association of the metabolic syndrome (Met S) with plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator (t-PA) antigen levels. Results. The overall prevalence of the Met S was 18%, was dependent on age and gender, and was positively associated with higher antigen levels of both PAI-1 and t-PA. These significant effects were maintained after adjustment for age, gender, BMI, elevated C-reactive protein, smoking status, urinary albumin excretion, and insulin levels. We found no significant interactions between the Met S and other covariates on PAI-1 and t-PA levels. Conclusions. Our study demonstrates that those with the Met S have significantly higher levels of PAI-1 and t-PA antigen, factors known to increase the risk of cardiovascular disease.

1. Introduction

The metabolic syndrome (Met S)—characterized by insulin resistance, abdominal obesity, hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, hypertension, and hyperglycemia—is becoming increasingly common. The Met S has been demonstrated to be a risk factor for cardiovascular disease [1] and type 2 diabetes [2]. Reported differences in the prevalence of the Met S among various ethnic groups [3] highlight the need to use population-based studies to examine descriptive epidemiology of the syndrome. Further, limited information is available on its association with plasminogen activator inhibitor type 1 (PAI-1) and tissue-type plasminogen activator (t-PA) antigen levels, both of which are biomarkers of fibrinolysis associated with an increased risk of cardiovascular disease [4–6]. We were also interested in how two more recently identified risk factors for cardiovascular disease—high-sensitivity (hs) C-reactive protein and microalbuminuria—might affect associations observed between the Met S and PAI-1 and t-PA antigen levels. High sensitivity C-reactive protein is a sensitive indicator of low-grade inflammation. C-reactive protein has been demonstrated to be an independent risk factor for cardiovascular disease [7, 8], and it is positively associated with both the Met S [9] and PAI-1 antigen levels [10]. Microalbuminuria, generally defined as a urinary albumin excretion of 30–300 mg per 24 hours [11], has been demonstrated to be an independent risk factor for
cardiovascular disease and mortality [12, 13]. Its appearance in the urine, in addition to renal pathology, indicates early vascular and endothelial damage in the vascular tree in general [14], and it is positively associated with both the Met S [15] and PAI-1 levels [16, 17].

While previous studies have generally reported positive associations between the Met S and PAI-1 and t-PA antigen levels [3, 18], few, if any, large population-based studies have controlled for C-reactive protein levels or albuminuria status or considered possible interactions between the Met S and other key variables on PAI-1 and t-PA antigen levels. The availability of a large population-based sample of subjects with detailed clinical data provided an opportunity to describe the Met S in a Dutch population and to examine the association of the Met S with PAI-1 and t-PA antigen levels, taking into account potential confounders and/or effect modifiers.

2. Materials and Methods

2.1. PREVEND Sample. This study is part of the ongoing Prevention of Renal and Vascular ENd-stage Disease (PREVEND) study, a large prospective study among inhabitants of the city of Groningen, the Netherlands. Details of the study protocol have been described elsewhere [12]. In brief, all inhabitants of the city between the ages of 28 and 75 (85,421 subjects) were asked to send in a morning urine sample and to fill out a short questionnaire on demographics and cardiovascular history. A total of 40,856 (47.8%) responded. From this group, 30,890 subjects had a urine sample and to fill out a short questionnaire on all inhabitants of the city of Groningen, the Netherlands. Details of the VEND) study, a large prospective study among inhabitants of Groningen, The Netherlands using ELISA kits from Technoclone GmbH (Vienna, Austria). These assays measured both free and bound PAI-1 and t-PA antigen levels and have been described in detail elsewhere [19].

The metabolic syndrome was the primary independent variable of interest. For the purposes of the described analyses, the Met S was defined using the modified criteria of the National Cholesterol Education Program, Third Adult Treatment Panel [20]. Individuals with 3 or more of the following components were categorized as having the overall syndrome: (1) abdominal obesity (waist measurement >102 cm for men and >88 cm for women); (2) hypertriglyceridemia (>1.69 mmol/L (150 mg/dL)); (3) low HDL cholesterol (≤1.03 mmol/L (40 mg/dL)) in men and ≤1.29 mmol/L (50 mg/dL) in women); (4) high blood pressure (≥130 mm Hg systolic and/or ≥85 mm Hg diastolic BP); (5) high fasting glucose (>5.5 mmol/L (100 mg/dL)). Waist and hip measurements were performed by several research nurses and medical students at the outpatient clinic for the PREVEND study. Waist circumference was measured on bare skin at the natural indentation between the 10th rib and iliac crest. Systolic and diastolic BPs were calculated as the average of the last two measurements taken at two clinic visits. After removal of shoes and heavy clothing, weight was measured to the nearest 0.5 kg using a Seca balance scale (Seca Vogel & Halke GmbH & Co, Hamburg, Germany). Height was measured to the nearest 0.5 cm. Blood samples were drawn after an overnight fast. Glucose was determined by Kodak Ektachem dry chemistry (Eastman Kodak, Rochester, NY, USA), an automatic enzymatic method. Triglycerides were measured enzymatically. A commercially available assay system was used to assess HDL cholesterol (Abbott Inc., Abbott Park, IL, USA). High-sensitivity C-reactive protein was determined by nephelometry with a threshold of 0.175 mg/L and intra- and interassay coefficients of less than 4.4% and 5.7%, respectively (BNIN, Dade Behring, Marburg, Germany).

Age was subdivided into categories of <40, 40–60, and >60 years of age. Smoking was defined as a current smoker or cessation of smoking less than a year before the study, BMI was subdivided into categories of <25, 25–30 (obese), and >30 (obese) kg/m². Elevated C-reactive protein was defined as a level >3 mg/L. Urinary albumin excretion (UAE) was measured as the mean of two 24-hour urine collections. Participants were categorized as having normoalbuminuria (<30 mg/24 h), microalbuminuria (30–300 mg/24 h), or macroalbuminuria (>300 mg/24 h). Insulin levels were subdivided into categories of <8, 8–12, and >12 µU/mL. Diabetes was defined as a fasting plasma glucose level >7.0 mmol/L, a nonfasting plasma glucose level >11.1 mmol/L, or the use of glucose-lowering medication.

2.2. Measurements. Stored plasma samples collected at baseline were thawed and assayed by the Haemoprobe laboratory (Groningen, The Netherlands) using ELISA kits from Technoclone GmbH (Vienna, Austria). These assays measured both free and bound PAI-1 and t-PA antigen levels and have been described in detail elsewhere [19].

The metabolic syndrome was the primary independent variable of interest. For the purposes of the described analyses, the Met S was defined using the modified criteria of the National Cholesterol Education Program, Third Adult Treatment Panel [20]. Individuals with 3 or more of the following components were categorized as having the overall syndrome: (1) abdominal obesity (waist measurement >102 cm for men and >88 cm for women); (2) hypertriglyceridemia (>1.69 mmol/L (150 mg/dL)); (3) low HDL cholesterol (≤1.03 mmol/L (40 mg/dL)) in men and ≤1.29 mmol/L (50 mg/dL) in women); (4) high blood pressure (≥130 mm Hg systolic and/or ≥85 mm Hg diastolic BP); (5) high fasting glucose (>5.5 mmol/L (100 mg/dL)). Waist and hip measurements were performed by several research nurses and medical students at the outpatient clinic for the PREVEND study. Waist circumference was measured on bare skin at the natural indentation between the 10th rib and iliac crest. Systolic and diastolic BPs were calculated as the average of the last two measurements taken at two clinic visits. After removal of shoes and heavy clothing, weight was measured to the nearest 0.5 kg using a Seca balance scale (Seca Vogel & Halke GmbH & Co, Hamburg, Germany). Height was measured to the nearest 0.5 cm. Blood samples were drawn after an overnight fast. Glucose was determined by Kodak Ektachem dry chemistry (Eastman Kodak, Rochester, NY, USA), an automatic enzymatic method. Triglycerides were measured enzymatically. A commercially available assay system was used to assess HDL cholesterol (Abbott Inc., Abbott Park, IL, USA). High-sensitivity C-reactive protein was determined by nephelometry with a threshold of 0.175 mg/L and intra- and interassay coefficients of less than 4.4% and 5.7%, respectively (BNIN, Dade Behring, Marburg, Germany).

Age was subdivided into categories of <40, 40–60, and >60 years of age. Smoking was defined as a current smoker or cessation of smoking less than a year before the study, BMI was subdivided into categories of <25, 25–30 (overweight), and >30 (obese) kg/m². Elevated C-reactive protein was defined as a level >3 mg/L. Urinary albumin excretion (UAE) was measured as the mean of two 24-hour urine collections. Participants were categorized as having normoalbuminuria (<30 mg/24 h), microalbuminuria (30–300 mg/24 h), or macroalbuminuria (>300 mg/24 h). Insulin levels were subdivided into categories of <8, 8–12, and >12 µU/mL. Diabetes was defined as a fasting plasma glucose level >7.0 mmol/L, a nonfasting plasma glucose level >11.1 mmol/L, or the use of glucose-lowering medication.
Table 1: Characteristics of the study population by presence or absence of the metabolic syndrome.

|                                | Metabolic syndrome |          | P value |
|--------------------------------|--------------------|----------|---------|
|                                | Present (N = 440)  | Absent (N = 2055) | <.0001 |
| Age at baseline                 |                    |          |         |
| <40 yrs (%)                    | 8.9                | 91.1     |         |
| 40–60 yrs (%)                  | 17.5               | 82.5     |         |
| >60 yrs (%)                    | 26.9               | 70.1     |         |
| Gender                         |                    |          |         |
| Male (%)                       | 20.9               | 79.1     | <.0001 |
| Female (%)                     | 14.8               | 85.2     |         |
| BMI                            |                    |          | <.0001 |
| <25 kg/m² (%)                  | 3.7                | 96.4     |         |
| 25–30 kg/m² (%)                | 22.7               | 77.3     |         |
| >30 kg/m² (%)                  | 53.1               | 47.0     |         |
| Smoker                         |                    |          | .5061   |
| Yes (%)                        | 18.4               | 81.6     |         |
| No (%)                         | 17.3               | 82.7     |         |
| C-reactive protein             |                    |          | <.0001 |
| ≥3.0 mg/L (%)                  | 33.0               | 67.0     |         |
| <3.0 mg/L (%)                  | 13.4               | 86.6     |         |
| Urinary albumin excretion      |                    |          | <.0001 |
| <30 mg/24 h (%)                | 15.7               | 84.3     |         |
| 30–300 mg/24 h (%)             | 44.9               | 55.2     |         |
| >300 mg/24 h (%)               | 80.0               | 20.0     |         |
| Insulin levels                 |                    |          | <.0001 |
| <8 µU/mL (%)                   | 5.1                | 94.9     |         |
| 8–12 µU/mL (%)                 | 18.6               | 81.4     |         |
| >12 µU/mL (%)                  | 45.3               | 54.7     |         |
| PAI-1 antigen (ng/mL) (median (IQR)) | 126.7 (81.4, 194.2) | 57.3 (35.5, 99.7) | <.0001 |
| t-PA antigen (ng/mL) (median (IQR)) | 3.9 (2.8, 6.0) | 2.9 (2.2, 4.2) | <.0001 |

BMI: body mass index; PAI-1: plasminogen activator inhibitor type 1; t-PA: tissue-type plasminogen activator; IQR: interquartile range.

1 Chi-square test, 2 T-test based on log values.

ranges (IQR) for summary statistics since such comparisons are more similar to a comparison of medians than means in the original metric. Univariate linear models were used to examine the individual effects of the Met S, age at baseline, gender, BMI, smoking status, elevated C-reactive protein, albuminuria status, and insulin levels with PAI-1 and t-PA levels. We also used multivariable linear regression models with backwards selection and split-sample validation to explore whether the association of the Met S with PAI-1 and t-PA levels held up after adjusting for the other variables. The full model of interest included all factors as well as all possible two-way interactions between each factor and the Met S. At each step, the interaction term with the highest P value (provided it was >.10) was removed from the model and the model was refit with all remaining terms. This process was continued until either no interaction terms remained or all remaining interactions were significant.

Since it is well known that models obtained using such data-driven methods are prone to increased type 1 errors [21], proper validation of such models is crucial. For this analysis, model validation was performed using the split-sample validation techniques as described in Muller and Fetterman [22]. Essentially, this involves splitting the analysis dataset into a training and hold-out sample. The shrinkage statistic is defined as the difference between the $R^2$ value in the final model obtained using the training sample and the cross-validity coefficient calculated from the holdout sample. Small values of relative shrinkage imply better generalizability of the final model. All statistical analyses were performed using SAS version 9.1.

3. Results and Discussion

3.1. Description of Met S in the Population. The average age of the study population was 48 years and 53% were women. The overall prevalence of the Met S in the population was 18% and rose with age in both genders. Although the overall prevalence was significantly higher in men than in women (21% versus 15%, $P < .01$), the prevalence was dependent on age and gender. As shown in Figure 1, in subjects less than 40 years, the prevalence was significantly higher in men (13% versus 6%, $P < .01$). In contrast, there was no significant
difference in the prevalence for men and women over 60 years (31% versus 29%, \( P = .46 \)).

Table 1 shows the characteristics of the study population by the presence or absence of the Met S. The Met S was positively associated with all covariates except smoking. We also examined the frequency of type 2 diabetes by the presence or absence of the Met S. The presence of diabetes was highly correlated with the Met S (75% of diabetics had the Met S versus 16% of nondiabetics, \( P < .001 \)).

3.2. Association of Met S and Other Covariates with PAI-1 Antigen Levels. The results from the univariate models indicate that an older age at baseline, male gender, higher BMI, smoking, elevated hs C-reactive protein, elevated UAE, and elevated insulin levels were positively associated with PAI-1 antigen levels (Table 2). In addition, PAI-1 levels were significantly higher among those with the Met S as opposed to those without the Met S (median (IQR): 3.9 (2.8, 6.0) ng/ml versus 2.9 (2.2, 4.2) ng/ml, \( P < .001 \)).

From the backwards selection algorithm using the training sample, there were no significant interactions. Cross-validation produced a negative shrinkage statistic which implies a reasonable fit. The results from the final multivariable model applied to the combined datasets are shown in Table 3. The previously observed relationships between t-PA levels and BMI, smoking status, and C-reactive protein disappear after adjustment. After adjustment for all other covariates, the Met S, increasing age at baseline, male gender, and elevated insulin levels continued to have a significant effect on t-PA levels.

3.4. Prevalence of Met S. The overall prevalence rate of 18% in our Dutch population and the greater prevalence in men as compared to women are similar to findings reported for other adult European populations. Hu et al. [23] reported an overall prevalence of the Met S of 15% in nondiabetic adult Europeans based on 11 study cohorts. If those with type 2 diabetes are removed from our Dutch population, the prevalence of the Met S is reduced to 16%, similar to that found in the study by Hu and others.

3.5. Association of Met S with PAI-1 and t-PA Antigen Levels. There remained a significant positive association between the Met S and both PAI-1 and t-PA antigen levels after adjustment for the covariates of interest. These associations also remained when participants with type 2 diabetes were excluded from the models (results not shown). Further, after adjustment all other covariates with the exception of UAE continued to have a significant effect on PAI-1 levels, whereas, in addition to the Met S, only age, gender, and insulin levels had significant effects on t-PA levels.

Our findings of an association between the Met S and PAI-1 and t-PA antigen levels are generally consistent with the findings of previously conducted studies [3, 18]. Anand et al. [3] also demonstrated a reduction in clot lysis time after induced ischemia by venous cuff occlusion, further supporting impaired fibrinolytic function in those with the Met S. Our study extends previous findings of an association between the Met S and PAI-1 and t-PA antigen levels by adjusting for a number of covariates and by exploring potential interactions between the Met S and these covariates.

The link between PAI-1 and Met S is complex, and several mechanisms could contribute to the elevated PAI-1 concentrations in Met S patients [24]. One of the proposed mechanisms is the contribution of the rennin-angiotensin system on PAI-1 synthesis. Angiotensin-converting enzyme inhibition has been shown to reduce PAI-1 levels in obese patients [25], and angiotensin II promotes PAI-1 excretion in human adipocytes [26]. In addition, the expression of rennin-angiotensin system genes is regulated differently in obese subjects [27], and a combination of variants in rennin-angiotensin system genes was associated with the Met S. Interestingly, our group previously found that polymorphisms in genes from the rennin, angiotensin, and
Table 2: PAI-1 antigen levels (ng/mL) for the association of the metabolic syndrome and other covariates.

| Table 2: PAI-1 antigen levels (ng/mL) for the association of the metabolic syndrome and other covariates. |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Age at baseline                                  | Median (IQR)                                   | Univariate models | Multivariable model |
| <40 yrs                                          | 51 (32, 89)                                   | <0.001            | <0.001             |
| 40–60 yrs                                        | 72 (42, 123)                                  | <0.001            | <0.001             |
| >60 yrs                                          | 80 (47, 138)                                  | <0.001            | <0.001             |
| Gender                                           |                                                | <0.001            | <0.001             |
| Male                                             | 75 (46, 132)                                  |                   |                   |
| Female                                           | 59 (34, 107)                                  |                   |                   |
| BMI                                              |                                                | <0.001            | <0.001             |
| <25 kg/m² (%)                                    | 49 (31, 79)                                   |                   |                   |
| 25–30 kg/m² (%)                                  | 80 (49, 143)                                  |                   |                   |
| >30 kg/m² (%)                                    | 115 (71, 189)                                 |                   |                   |
| Smoking status                                   |                                                | <0.001            | <0.001             |
| Current/former                                   | 70 (43, 126)                                  |                   |                   |
| Nonsmokers                                       | 64 (37, 114)                                  |                   |                   |
| C-reactive protein                               |                                                | <0.001            |                   |
| ≥3.0 mg/L                                        | 84 (45, 152)                                  |                   | 0.633              |
| <3.0 mg/L                                        | 63 (38, 109)                                  |                   |                   |
| Urinary albumin excretion                        |                                                | <0.001            | 0.303              |
| <30 mg/24 h (%)                                  | 66 (39, 116)                                  |                   |                   |
| 30–300 mg/24 h (%)                               | 80 (48, 154)                                  |                   |                   |
| >300 mg/24 h (%)                                 | 104 (68, 134)                                 |                   |                   |
| Insulin levels                                   |                                                | <0.001            | <0.001             |
| <8 µU/mL (%)                                     | 52 (34, 82)                                   |                   |                   |
| 8–12 µU/mL (%)                                   | 77 (44, 128)                                  |                   |                   |
| >12 µU/mL (%)                                    | 114 (71, 181)                                 |                   |                   |
| Metabolic syndrome                               |                                                | <0.001            | <0.001             |
| Present                                          | 126 (81, 194)                                 |                   |                   |
| Absent                                           | 59 (36, 103)                                  |                   |                   |

PAI-1 levels were missing in 29 (1.2%) of subjects.

bradykinin system were related to PAI-1 and t-PA levels and this relationship was dependent on body size as assessed by body mass index and waist-to-hip ratio [28, 29]. Further research is needed to further elucidate the underlying mechanisms responsible for the observed relation between PAI-1, t-PA, and the Met S.

The positive associations of PAI-1 with age, male gender, BMI, smoking, and insulin levels as well as the positive associations of t-PA with age, male gender, and insulin levels have been reported elsewhere [10, 30–35]. The lack of association between C-reactive protein with PAI-1 and t-PA levels is interesting and may suggest that the elevation of PAI-1 may be due to production of PAI-1 by adipose tissue and less as a response to changes in inflammatory status. This lack of association has been reported previously [36]. The lack of association of UAE with PAI-1 levels and of smoking and obesity with t-PA levels was unanticipated since associations have been previously reported [16, 17, 31, 37].

3.6. Strengths and Limitations. Strengths of our research include the fact that the sample used for analysis was population-based and therefore more representative of the general adult population than would be other population groups. Further, our sample size was relatively large and we had data available on a large number of variables including hs C-reactive protein and UAE, novel risk factors for cardiovascular disease associated with both the Met S and PAI-1 antigen levels.

There were also several limitations of our study. As our study was cross-sectional, although the associations between the Met S and PAI-1 and t-PA antigen levels remained after control for other covariates, we are unable to evaluate causality. One possibility, consistent with the hypothesis that the increase in cardiovascular disease among individuals with the Met S occurs at least in part through thrombotic mechanisms, is that the Met S causes elevations of PAI-1 and t-PA levels. Alternatively, it has been hypothesized that PAI-1 levels may play a causal role in the development of obesity and the Met S [24]. This is a promising hypothesis as PAI-1 was recently demonstrated to predict the development of type 2 diabetes in the prospective Insulin Resistance Atherosclerosis Study (IRAS) [38]. Hence, the choice of PAI-1 and t-PA antigen levels as the endpoints for the study was somewhat arbitrary since, although the
Table 3: t-PA antigen levels (ng/mL) for the association of the metabolic syndrome and other covariates.

| Covariate                  | Median (IQR) | Univariate models | Multivariable model |
|----------------------------|--------------|-------------------|---------------------|
| Age at baseline            |              | <0.001            | <0.001              |
| <40 yrs                    | 2.7 (1.9, 3.5) |                   |                     |
| 40–60 yrs                  | 3.1 (2.3, 4.4) |                   |                     |
| >60 yrs                    | 3.7 (2.7, 5.7) |                   |                     |
| Gender                     |              | <0.001            | <0.001              |
| Male                       | 3.3 (2.4, 4.9) |                   |                     |
| Female                     | 2.8 (2.1, 4.0) |                   |                     |
| BMI                        |              | 0.153             |                     |
| <25 kg/m² (%)              | 2.7 (2.1, 3.7) |                   |                     |
| 25–30 kg/m² (%)            | 3.4 (2.4, 5.1) |                   |                     |
| >30 kg/m² (%)              | 3.6 (2.6, 4.9) |                   |                     |
| Smoking status             |              | 0.042             | 0.391               |
| Current/former             | 3.0 (2.2, 4.4) |                   |                     |
| Nonsmokers                 | 3.1 (2.3, 4.5) |                   |                     |
| C-reactive protein         |              | 0.001             | 0.418               |
| ≥3.0 mg/L                  | 3.3 (2.3, 4.9) |                   |                     |
| <3.0 mg/L                  | 3.0 (2.2, 4.3) |                   |                     |
| Urinary albumin excretion  |              | 0.10              | 0.383               |
| <30 mg/24 h (%)            | 3.0 (2.2, 4.4) |                   |                     |
| 30–300 mg/24 h (%)         | 3.3 (2.4, 5.0) |                   |                     |
| >300 mg/24 h (%)           | 4.6 (4.2, 6.3) |                   |                     |
| Insulin levels             |              | <0.001            | <0.001              |
| <8 µU/mL (%)               | 2.8 (2.1, 3.8) |                   |                     |
| 8–12 µU/mL (%)             | 3.2 (2.3, 4.7) |                   |                     |
| >12 µU/mL (%)              | 3.6 (2.6, 5.7) |                   |                     |
| Metabolic syndrome         |              | <0.001            | 0.002               |
| Present                    | 3.9 (2.8, 6.0) |                   |                     |
| Absent                     | 2.9 (2.2, 4.2) |                   |                     |

t-PA levels were missing in 26 (1.0%) of subjects.

Met S may influence PAI-1 and t-PA levels, PAI-1 has also been hypothesized to causally influence obesity and the Met S. It would also be of interest to know whether the subjects were on statin therapy, receiving other lipid lowering drugs, or receiving ACE inhibitors or ARBs. Unfortunately, the PREVEND database does not include detailed information regarding the use of statins or ARBs. Only a small percentage of subjects were found to be receiving any ACE inhibitor (4.4%) or any lipid lowering medication (5.0%), which suggests that this would have a minimal impact on the overall conclusions of the study. Finally, due to the size of the study and the curse of dimensionality, we did not explore interactions among the covariates of interest nor did we explore interactions higher than second order among the covariates and the Met S. Hence, we may have missed an important higher-order interaction among the variables of interest.

4. Conclusions

In conclusion, the present study demonstrates that those with the Met S have higher levels of PAI-1 and t-PA antigen, factors known to increase the risk of cardiovascular disease. However, prospective studies are needed to establish causality. To demonstrate that the Met S causes increases in PAI-1 and t-PA antigen levels that result in cardiovascular disease requires monitoring changes in these fibrinolytic variables, in addition to the development of clinical events,
in subjects with and without the Met S. Alternatively, to determine if PAI-1 is an underlying cause of the Met S would require examining the associations of baseline levels of PAI-1 with incident cases of the Met S. After causality is established, clinical trials will be needed to investigate whether lifestyle or pharmacologic interventions targeted to improve fibrinolytic function reduce cardiovascular events in subjects with the Met S or, alternatively, are effective in preventing the Met S.

Acknowledgments

This work was supported by National Institutes of Health (NIH) Grant HL65234, HL67466, RR018787, and LM010098 and by Grant E.013 of Netherlands Kidney Foundation. Dr. F. W. Asselbergs is supported by a ZonMW Clinical Fellowship (Grant 90700342). A portion of the work was described in a paper submitted by Q. Li in partial fulfillment of the requirements for the M.S. degree in biostatistics at the University of Alabama at Birmingham. The authors would like to thank the Associate Editor and two anonymous reviewers for helpful comments on an earlier version of the paper. The authors have no conflict of interests to report.

References

[1] A. S. Gami, B. J. Witt, D. E. Howard et al., “Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies,” Journal of the American College of Cardiology, vol. 49, no. 4, pp. 403–414, 2007.
[2] D. E. Laaksonen, H. M. Lakka, L. K. Niskanen, G. A. Kaplan, J. T. Salonen, and T. A. Lakka, “Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study,” American Journal of Epidemiology, vol. 156, no. 11, pp. 1070–1077, 2002.
[3] S. S. Anand, Q. Yi, H. Gerstein et al., “Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease,” Circulation, vol. 108, no. 4, pp. 420–425, 2003.
[4] P. M. Ridker, D. E. Vaughan, M. J. Stampfer, J. E. Manson, and C. H. Hennekens, “Endogenous tissue-type plasminogen activator and risk of myocardial infarction,” The Lancet, vol. 341, no. 8854, pp. 1165–1168, 1993.
[5] A. R. Folsom, N. Alekisic, E. Park, V. Salomaa, H. Juneja, and K. K. Wu, “Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 4, pp. 611–617, 2001.
[6] I. Mertens, A. Verrijken, J. J. Michiels, M. van der Planken, J. B. Ruige, and L. F. van Gaal, “Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome,” International Journal of Obesity, vol. 30, no. 8, pp. 1308–1314, 2006.
[7] P. M. Ridker, M. Cushman, M. J. Stampfer, R. P. Tracy, and C. H. Hennekens, “Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men,” The New England Journal of Medicine, vol. 336, no. 14, pp. 973–979, 1997.
[8] P. M. Ridker, C. H. Hennekens, J. E. Buring, and N. Rifai, “C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women,” The New England Journal of Medicine, vol. 342, no. 12, pp. 836–843, 2000.
[9] E. S. Ford, W. H. Giles, and W. H. Dietz, “Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey,” Journal of the American Medical Association, vol. 287, no. 3, pp. 356–359, 2002.
[10] J. S. Yudkin, C. D. A. Stehouwer, J. J. Emeis, and S. W. Coppick, “C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 4, pp. 972–978, 1999.
[11] C. E. Mogensen, W. F. Keane, P. H. Bennett et al., “Prevention of diabetic renal disease with special reference to microalbuminuria,” The Lancet, vol. 346, no. 8982, pp. 1080–1084, 1995.
[12] H. L. Hillege, V. Fidler, G. F. H. Diercks et al., “Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population,” Circulation, vol. 106, no. 14, pp. 1777–1782, 2002.
[13] K. Borch-Johnsen, B. Feldt-Rasmussen, S. Strandgaard, M. Schroll, and J. S. Jensen, “Urinary albumin excretion: an independent predictor of ischemic heart disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 8, pp. 1992–1997, 1999.
[14] L. Mykkänen, D. J. Zaccaro, D. H. O’Leary, G. Howard, D. C. Robbins, and S. M. Haffner, “Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects: the Insulin Resistance Atherosclerosis Study (IRAS),” Stroke, vol. 28, no. 9, pp. 1710–1716, 1997.
[15] L. Palaniappan, M. Carnethon, and S. P. Fortmann, “Association between microalbuminuria and the metabolic syndrome: NHANES III,” American Journal of Hypertension, vol. 16, no. 11, pp. 952–958, 2003.
[16] T. Hirano, K. Kashiwazaki, Y. Moritomo, S. Nagano, and M. Adachi, “Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients,” Diabetes Research and Clinical Practice, vol. 36, no. 1, pp. 11–18, 1997.
[17] S. Agewall, G. Lindstedt, and B. Fagerberg, “Independent relationship between microalbuminuria and plasminogen activator inhibitor-1 activity (PAI-1) activity in clinically healthy 58-year-old men,” Atherosclerosis, vol. 157, no. 1, pp. 197–202, 2001.
[18] J. B. Meigs, M. A. Mittleman, D. M. Nathan et al., “Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study,” Journal of the American Medical Association, vol. 283, no. 2, pp. 221–228, 2000.
[19] F. W. Asselbergs, S. M. Williams, P. R. Hebert et al., “The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin system in determining plasma t-PA and PAI-I levels,” Thrombosis and Haemostasis, vol. 96, no. 4, pp. 471–477, 2006.
[20] S. M. Grundy, H. B. Brewer Jr., J. I. Cleeman, and S. C. Smith Jr., “Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition,” Circulation, vol. 109, no. 3, pp. 433–438, 2004.
[21] F. E. Harrell, Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis, chapter 5, Springer, New York, NY, USA, 2001.
[22] K. E. Muller and B. A. Fetterman, Regression and ANOVA: an Integrated Approach Using SAS® Software, chapter 11, SAS Institute, Cary, NC, USA, 2002.

[23] G. Hu, Q. Qiao, J. Tuomilehto, B. Balkau, K. Borch-Johnsen, and K. Pyorala, “Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women,” Archives of Internal Medicine, vol. 164, no. 10, pp. 1066–1076, 2004.

[24] M. C. Alessi and I. Juhan-Vague, “PAI-1 and the metabolic syndrome: links, causes, and consequences,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 10, pp. 2200–2207, 2006.

[25] N. J. Brown, M. A. Agirbasli, G. H. Williams, W. R. Litchfield, and D. E. Vaughan, “Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1,” Hypertension, vol. 32, no. 6, pp. 965–971, 1998.

[26] T. Skurk, Y. M. Lee, and H. Hauner, “Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture,” Hypertension, vol. 37, no. 5, pp. 1336–1340, 2001.

[27] K. Gorzelniak, S. Engel, J. Janke, F. C. Luft, and A. M. Sharma, “Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension,” Journal of Hypertension, vol. 20, no. 5, pp. 965–973, 2002.

[28] F. W. Asselbergs, S. M. Williams, P. R. Hebert et al., “Epistatic effects of polymorphisms in genes from the rennin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels,” Genomics, vol. 89, pp. 362–369, 2007.

[29] F. W. Asselbergs, S. M. Williams, P. R. Hebert et al., “The effects of polymorphisms in genes from the rennin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels are dependent on environmental context,” Human Genetics, vol. 122, pp. 275–281, 2007.

[30] G. H. Tofler, J. Massaro, D. Levy et al., “Relation of the prothrombotic state to increasing age (from the Framingham Offspring Study),” American Journal of Cardiology, vol. 96, no. 9, pp. 1280–1283, 2005.

[31] J. W. G. Yarnell, P. M. Sweetnam, A. Rumley, and G. D. O. Lowe, “Lifestyle and hemostatic risk factors for ischemic heart disease: the Caerphilly Study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 1, pp. 271–279, 2000.

[32] P.-Y. Scarabin, M.-F. Aillaud, P. Amouyel et al., “Association of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction. The PRIME Study. Prospective Epidemiological Study of Myocardial Infarction,” Thrombosis and Haemostasis, vol. 80, no. 5, pp. 749–756, 1998.

[33] D. J. Schneider and B. E. Sobel, “Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 22, pp. 9959–9963, 1991.

[34] F. W. Asselbergs, S. M. Williams, P. R. Hebert et al., “Gender-specific correlations of plasminogen activator inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits,” Journal of Thrombosis and Haemostasis, vol. 5, no. 2, pp. 313–320, 2007.

[35] J. A. Schoenhart, F. W. Asselbergs, K. A. Poku et al., “Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population,” Human Genetics, vol. 124, no. 5, pp. 479–488, 2008.

[36] P. A. Sakkonen, P. Wahl, M. Cushman, M. R. Lewis, and R. P. Tracy, “Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome,” American Journal of Epidemiology, vol. 152, no. 10, pp. 897–907, 2000.

[37] G. A. Rosito, R. B. D’Agostino, J. Massaro et al., “Association between obesity and a prothrombotic state: the Framingham Offspring Study,” Thrombosis and Haemostasis, vol. 91, no. 4, pp. 683–689, 2004.

[38] A. Festa, R. D’Agostino, R. P. Tracy, and S. M. Haffner, “Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study,” Diabetes, vol. 51, no. 4, pp. 1131–1137, 2002.